- Home
- GEVO vs CRVS Comparison
GEVO vs CRVS Comparison
Compare GEVO & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEVO
- CRVS
- Stock Information
- Founded
- GEVO 2005
- CRVS 2014
- Country
- GEVO United States
- CRVS United States
- Employees
- GEVO N/A
- CRVS N/A
- Industry
- GEVO Major Chemicals
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- GEVO Industrials
- CRVS Health Care
- Exchange
- GEVO Nasdaq
- CRVS Nasdaq
- Market Cap
- GEVO 246.8M
- CRVS 206.5M
- IPO Year
- GEVO 2011
- CRVS 2016
- Fundamental
- Price
- GEVO $1.26
- CRVS $3.78
- Analyst Decision
- GEVO Buy
- CRVS Strong Buy
- Analyst Count
- GEVO 2
- CRVS 4
- Target Price
- GEVO $7.58
- CRVS $15.00
- AVG Volume (30 Days)
- GEVO 3.5M
- CRVS 1.4M
- Earning Date
- GEVO 05-13-2025
- CRVS 05-08-2025
- Dividend Yield
- GEVO N/A
- CRVS N/A
- EPS Growth
- GEVO N/A
- CRVS N/A
- EPS
- GEVO N/A
- CRVS N/A
- Revenue
- GEVO $42,034,000.00
- CRVS N/A
- Revenue This Year
- GEVO $631.78
- CRVS N/A
- Revenue Next Year
- GEVO $80.71
- CRVS N/A
- P/E Ratio
- GEVO N/A
- CRVS N/A
- Revenue Growth
- GEVO 145.38
- CRVS N/A
- 52 Week Low
- GEVO $0.48
- CRVS $1.75
- 52 Week High
- GEVO $3.39
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- GEVO 65.60
- CRVS 54.46
- Support Level
- GEVO $1.00
- CRVS $3.38
- Resistance Level
- GEVO $1.39
- CRVS $3.94
- Average True Range (ATR)
- GEVO 0.08
- CRVS 0.25
- MACD
- GEVO 0.02
- CRVS 0.01
- Stochastic Oscillator
- GEVO 87.22
- CRVS 34.78
About GEVO Gevo Inc.
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).